Brad H Nelson

List of Publications by Year
in descending order

125 papers	14,347 citations	30070 54 h-index	20961 115 g-index
131 all docs	131 docs citations	131 times ranked	21160 citing authors

#	Article	IF	Citations
1	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	2.5	2
2	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
3	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	8.2	12
4	Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nature Reviews Cancer, 2022, 22, 414-430.	28.4	109
5	MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues. Cancer Immunology, Immunotherapy, 2022, 71, 1259-1273.	4.2	5
6	Breaching B cell tolerance in the tumor microenvironment. Cancer Cell, 2022, 40, 356-358.	16.8	1
7	Tumour immunotherapy: lessons from predatorâ€“prey theory. Nature Reviews Immunology, 2022, 22, 765-775.	22.7	41
8	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Gynecologic Oncology, 2021, 160, 520-529.	1.4	10
9	Avelumab in newly diagnosed glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab118.	0.7	8
10	CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1538-1552.	7.0	39
11	Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. Clinical Cancer Research, 2021, 27, 4089-4100.	7.0	46
12	IgA transcytosis: A new weapon in the immune response to cancer?. Cancer Cell, 2021, 39, 607-609.	16.8	2
13	Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. Communications Biology, 2021, 4, 859.	4.4	13
14	B cells and cancer. Cancer Cell, 2021, 39, 1293-1296.	16.8	52
15	1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. Science Advances, 2021, 7, .	10.3	46
16	Loss of Parkinsonâ€™s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. Scientific Reports, 2021, 11, 2097.	3.3	22
17	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	26
18	Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. Npj Precision Oncology, 2021, 5, 103.	5.4	18

#	Article	IF	Citations
19	Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Cancer Discovery, 2020, 10, 406-421.	9.4	155
20	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers, 2020, 12, 3828.	3.7	19
21	The MOCOG study: Learning from extraordinary responders to improve treatment outcomes for women with ovarian cancer. Pathology, 2020, 52, S30-S31.	0.6	0
22	The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecologic Oncology, 2020, 158, 167-177.	1.4	20
23	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget, 2020, 11, 2092-2105.	1.8	64
24	Single Cell Profiling Reveals Unique CXCL13 Positive T Cell Subsets in the Tumor Microenvironment of Lymphocyte Rich Classic Hodgkin Lymphoma. Blood, 2020, 136, 32-33.	1.4	0
25	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Reports, 2019, 29, 2338-2354.e7.	6.4	74
26	Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews Cancer, 2019, 19, 339-348.	28.4	35
27	Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9020-9029.	7.1	372
28	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	4.1	39
29	Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. , 2019, 7, 13.		37
30	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 2537-2548.	7.0	101
31	Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nature Medicine, 2019, 25, 89-94.	30.7	413
32	Oncolytic viruses as engineering platforms for combination immunotherapy. Nature Reviews Cancer, 2018, 18, 419-432.	28.4	288
33	A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. OncoImmunology, 2018, 7, e1371895.	4.6	35
34	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	2.6	67
35	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	7.0	79
36	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. OncoImmunology, 2018, 7, e1502905.	4.6	80

#	Article	IF	Citations
37	Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer. Clinical Cancer Research, 2018, 24, 6125-6135.	7.0	287
38	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22.	28.9	261
39	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. OncoImmunology, 2017, 6, e1321184.	4.6	23
40	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	4.3	530
41	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	4.3	469
42	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. Clinical Cancer Research, 2017, 23, 925-934.	7.0	125
43	PD-L1 and intratumoral immune response in breast cancer. Oncotarget, 2017, 8, 51641-51651.	1.8	37
44	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS ONE, 2016, 11, e0155189.	2.5	112
45	CD103 and Intratumoral Immune Response in Breast Cancer. Clinical Cancer Research, 2016, 22, 6290-6297.	7.0	125
46	Oncolytic vesicular stomatitis virus expressing interferon-Ïƒ has enhanced therapeutic activity. Molecular Therapy - Oncolytics, 2016, 3, 16001.	4.4	63
47	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Nonâ€“small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	2.5	30
48	Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433.		1
49	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. Clinical Chemistry, 2016, 62, 1238-1247.	3.2	45
50	Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 3005-3015.	7.0	402
51	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clinical Cancer Research, 2016, 22, 2226-2236.	7.0	26
52	PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecologic Oncology, 2016, 141, 293-302.	1.4	261
53	PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Cancer Immunology Research, 2015, 3, 926-935.	3.4	169
54	CD25 Identifies a Subset of CD4+FoxP3â^' TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer. Cancer Immunology Research, 2015, 3, 245-253.	3.4	32

#	Article	IF	Citations
55	New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Current Opinion in Immunology, 2015, 33, 93-100.	5.5	33
56	The more tumors change, the more they stay tame: Do T cells keep POLE ultramutated endometrial carcinomas in check?. Gynecologic Oncology, 2015, 138, 1-2.	1.4	14
57	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
58	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Annals of Oncology, 2015, 26, 2367-2374.	1.2	40
59	Location, location, location. OncoImmunology, 2014, 3, e27668.	4.6	53
60	Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy. OncoImmunology, 2014, 3, e29243.	4.6	10
61	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Research, 2014, 24, 743-750.	5.5	534
62	Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1125-1134.	7.0	144
63	Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2014, 20, 434-444.	7.0	340
64	Clonal evolution of highâ€grade serous ovarian carcinoma from primary to recurrent disease. Journal of Pathology, 2013, 229, 515-524.	4.5	88
65	Dysregulated Hematopoiesis Caused by Mammary Cancer Is Associated with Epigenetic Changes and Hox Gene Expression in Hematopoietic Cells. Cancer Research, 2013, 73, 5892-5904.	0.9	39
66	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Modern Pathology, 2012, 25, 740-750.	5.5	151
67	The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature. Clinical Cancer Research, 2012, 18, 3022-3029.	7.0	390
68	Tumor-infiltrating B cells and T cells. OncoImmunology, 2012, 1, 1623-1625.	4.6	77
69	CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27â^' Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. Clinical Cancer Research, 2012, 18, 3281-3292.	7.0	447
70	Killer T cells to the rescue in ovarian cancer. Gynecologic Oncology, 2012, 124, 178-179.	1.4	0
71	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. Journal of Translational Medicine, 2012, 10, 33.	4.4	93
72	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139

#	Article	IF	Citations
73	Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine, 2011, 29, 984-993.	3.8	40
74	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Research, 2011, 13, R126.	5.0	315
75	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood, 2011, 118, 4853-4862.	1.4	144
76	A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation. Cancer Research, 2011, 71, 4484-4493.	0.9	110
77	ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma. PLoS Biology, 2011, 9, e1001156.	5.6	50
78	Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model. Breast Cancer Research and Treatment, 2010, 121, 753-763.	2.5	9
79	An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. Journal of Immunological Methods, 2010, 360, 149-156.	1.4	15
80	Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (Î±E/Î²7) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	59
81	A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients. Clinical Cancer Research, 2010, 16, 4046-4056.	7.0	53
82	CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes. Journal of Immunology, 2010, 185, 4977-4982.	0.8	360
83	Polyfunctional T-Cell Responses Are Disrupted by the Ovarian Cancer Ascites Environment and Only Partially Restored by Clinically Relevant Cytokines. PLoS ONE, 2010, 5, e15625.	2.5	27
84	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. PLoS ONE, 2009, 4, e6412.	2.5	354
85	Profiling model T-cell metagenomes with short reads. Bioinformatics, 2009, 25, 458-464.	4.1	43
86	IDO and outcomes in ovarian cancer. Gynecologic Oncology, 2009, 115, 179-180.	1.4	12
87	Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgenâ€dependent murine tumor model. International Journal of Cancer, 2009, 125, 2871-2878.	5.1	7
88	Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunology, Immunotherapy, 2009, 58, 1865-1875.	4.2	9
89	Uncoupling IL-2 Signals that Regulate T Cell Proliferation, Survival, and Fas-Mediated Activation-Induced Cell Death. Immunity, 2009, 30, 611.	14.3	3
90	Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Research, 2009, 19, 1817-1824.	5.5	361

#	Article	IF	Citations
91	The impact of Tâ€cell immunity on ovarian cancer outcomes. Immunological Reviews, 2008, 222, 101-116.	6.0	144
92	Ovarian Cancer Early Detection Claims Are Biased. Clinical Cancer Research, 2008, 14, 7574.1-7574.	7.0	37
93	Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer. PLoS ONE, 2008, 3, e2633.	2.5	74
94	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. PLoS ONE, 2008, 3, e3409.	2.5	37
95	Effects of Standard Treatments on the Immune Response to Prostate Cancer. , 2008, , 531-555.		0
96	STAT5 Is Essential for Akt/p70S6 Kinase Activity during IL-2-Induced Lymphocyte Proliferation. Journal of Immunology, 2007, 179, 5301-5308.	0.8	49
97	CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15â€"Dependent Mechanism. Clinical Cancer Research, 2007, 13, 7172-7180.	7.0	19
98	Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer. Clinical Cancer Research, 2007, 13, 1493-1502.	7.0	157
99	Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells. Cancer Research, 2007, 67, 6442-6450.	0.9	30
100	Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers. PLoS ONE, 2007, 2, e1281.	2.5	42
101	Application of Bayesian Modeling of Autologous Antibody Responses against Ovarian Tumor-Associated Antigens to Cancer Detection. Cancer Research, 2006, 66, 1792-1798.	0.9	34
102	Transcription-induced Chromatin Remodeling at the c-myc Gene Involves the Local Exchange of Histone H2A.Z. Journal of Biological Chemistry, 2005, 280, 25298-25303.	3.4	78
103	FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism. Molecular and Cellular Biology, 2004, 24, 10058-10071.	2.3	155
104	Proliferation and Differentiation of CD8+ T Cells in the Absence of IL-2/15 Receptor Î²-Chain Expression or STAT5 Activation. Journal of Immunology, 2004, 173, 3131-3139.	0.8	19
105	A Permissive Role for Phosphatidylinositol 3-Kinase in the Stat5- mediated Expression of Cyclin D2 by the Interleukin-2 Receptor. Journal of Biological Chemistry, 2004, 279, 5520-5527.	3.4	51
106	IL-2, Regulatory T Cells, and Tolerance. Journal of Immunology, 2004, 172, 3983-3988.	0.8	532
107	Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. International Journal of Cancer, 2003, 104, 73-84.	5.1	65
108	Uncoupling of Promitogenic and Antiapoptotic Functions of IL-2 by Smad-Dependent TGF-Î² Signaling. Journal of Immunology, 2003, 170, 5563-5570.	0.8	33

#	Article	IF	Citations
109	Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3001-3006.	7.1	102
110	MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily. Gene, 2001, 267, 173-182.	2.2	27
111	Interleukin-2 Signaling and the Maintenance of Self-Tolerance. , 2001, 5, 92-112.		46
112	Phosphatidylinositol 3-Kinase Potentiates, but Does Not Trigger, T Cell Proliferation Mediated by the IL-2 Receptor. Journal of Immunology, 2001, 167, 2714-2723.	0.8	51
113	Stat5 and Sp1 Regulate Transcription of the Cyclin D2 Gene in Response to IL-2. Journal of Immunology, 2001, 166, 1723-1729.	0.8	93
114	The IL-2 Receptor Promotes Lymphocyte Proliferation and Induction of the c-myc, bcl-2, and bcl-x Genes Through the trans-Activation Domain of Stat5. Journal of Immunology, 2000, 164, 2533-2541.	0.8	212
115	New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway. Molecular and Cellular Biology, 2000, 20, 7109-7120.	2.3	241
116	Expression of Chimeric Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin 2 Receptors in Human Cytotoxic T Lymphocyte Clones Results in Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Growth. Human Gene Therapy, 1999, 10, 1941-1951.	2.7	21
117	Role of Interleukin (IL)-2 Receptor Î²-Chain Subdomains and Shc in p38 Mitogen-activated Protein (MAP) Kinase and p54 MAP Kinase (Stress-activated Protein Kinase/c-Jun N-terminal Kinase) Activation. Journal of Biological Chemistry, 1999, 274, 7591-7597.	3.4	32
118	Homodimerization of IL-2 receptor Î² chain is necessary and sufficient to activate Jak2 and dowstream signaling pathways. FEBS Letters, 1998, 421, 32-36.	2.8	12
119	Biology of the Interleukin-2 Receptor. Advances in Immunology, 1998, 70, 1-81.	2.2	420
120	Interleukin 2 Receptor. , 1998, , 1439-1442.		1
121	The Apoptosis-inducing Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Analog E21R Functions through Specific Regions of the Heterodimeric GM-CSF Receptor and Requires Interleukin-1Î²-converting Enzyme-like Proteases. Journal of Biological Chemistry, 1997, 272, 9877-9883.	3.4	14
122	Cytoplasmic domains of the interleukin-2 receptor Î² and Î³ chains mediate the signal for T-cell proliferation. Nature, 1994, 369, 333-336.	27.8	321
123	Genetic Modification of T Cell Clones to Improve the Safety and Efficacy of Adoptive T Cell Therapy. Novartis Foundation Symposium, 1994, 187, 212-228.	1.1	0
124	The Multifaceted Roles of B Cells and Plasma Cells in Antitumor Immunity. , 0, , .		1
125	Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis. Melanoma Research, 0, Publish Ahead of Print, .	1.2	4